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Abstract
Background: Lynch syndrome is a hereditary cancer with confirmed carriers at high risk for colorectal (CRC) and
extracolonic cancers. The purpose of the current study was to develop a greater understanding of the factors
influencing decisions about disease management post-genetic testing.
Methods: The study used a grounded theory approach to data collection and analysis as part of a multiphase
project examining the psychosocial and behavioral impact of predictive DNA testing for Lynch syndrome.
Individual and small group interviews were conducted with individuals from 10 families with the MSH2 intron 5
splice site mutation or exon 8 deletion. The data from confirmed carriers (n = 23) were subjected to re-analysis to
identify key barriers to and/or facilitators of screening and disease management.
Results: Thematic analysis identified personal, health care provider and health care system factors as dominant
barriers to and/or facilitators of managing Lynch syndrome. Person-centered factors reflect risk perceptions and
decision-making, and enduring screening/disease management. The perceived knowledge and clinical
management skills of health care providers also influenced participation in recommended protocols. The health
care system barriers/facilitators are defined in terms of continuity of care and coordination of services among
providers.
Conclusions: Individuals with Lynch syndrome often encounter multiple barriers to and facilitators of disease
management that go beyond the individual to the provider and health care system levels. The current
organization and implementation of health care services are inadequate. A coordinated system of local services
capable of providing integrated, efficient health care and follow-up, populated by providers with knowledge of
hereditary cancer, is necessary to maintain optimal health.
Introduction
The increased use of predictive DNA testing to deter-
mine the hereditary basis of familial cancer has impor-
tant implications for cognitive, affective and behavioral
outcomes of high risk individuals. Investigations into the
impact of genetic testing have focused more on cogni-
tive and affective responses and less on factors facilitat-
ing optimal disease management. Our understanding of
behavioral responses is a significant gap in the research
literature.
The most common hereditary colon cancer is Lynch
syndrome [1-4] which is an autosomal dominant disease
accounting for 2-5% of all colorectal cancers (CRCs)
worldwide [1,5], with geographical clusterings observed
[5,6]. A puzzling and unexplained feature of the disease
is the variable expressivity (differing ages of onset, can-
cer sites) and incomplete penetrance (not all carriers
develop the disease) [6,7]. Lynch syndrome has a life-
time CRC risk of about 80% [7,8] and is also associated
with extracolonic cancers of the uterus, ovary, kidney,
urinary tract, stomach, biliary tract, small intestine and
brain [8]. Gynecologic cancers are important for female
carriers who have a lifetime risk of 40-60% for endome-
trial and 10-21% for ovarian cancers [4,6].
Confirmation of Lynch syndrome means that all
family members should undergo predictive DNA testing
and/or be strongly encouraged to regularly screen. The
effectiveness of screening in reducing morbidity and
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this, there is suboptimal uptake of screening by high
risk individuals [11-13]. Wide variability in adherence
rates have been reported, with colonoscopy screening
ranging from 53-100% [11,14-20], transvaginal ultraso-
nography from 69-86% [14,20,21] and endometrial biop-
sies around 54% [21].
From a clinical management perspective, it is impor-
tant to know why some high risk individuals fail to fol-
low recommended guidelines. Few research inquiries
have attempted to identify facilitators of, or barriers to,
behavioral change following confirmation of hereditary
disease [22-28]. Merely informing individuals of their
cancer risk may not motivate behavior change [25] and
could possibly impede screening if perceived to be
uncontrollable [29,30].
Some authors have conjectured that awareness of
familial cancer patterns and personal/family cancer
experiences influence risk perceptions which, in turn,
impact acceptance of a carrier status and engagement
with screening [25-27,30-32]. Other authors have used
social cognition theory as a template for conceptualizing
cognitive and emotional factors that impact reactions to
predictive DNA testing and, ultimately, behavioral
responses [25,30,31]. Nevertheless, it remains unclear
how risk perceptions are shaped by disease-related
experiences and impact behavior.
High risk individuals are expected to manage their
cancer risk [16,21,33]. This can be difficult without con-
sensus on the scope, frequency, and age of initiation of
screening for CRC [4,34-37] and extracolonic cancers
[4,34,35,38]. Despite the documented benefits of prophy-
lactic interventions, like gynecologic surgeries, for redu-
cing cancer risk [4,34,38], these strategies have not been
fully integrated into the clinical management of Lynch
syndrome families.
Health care providers play a key role in encouraging
high risk individuals to become involved in disease man-
agement [4,34,35,39]. It is critical that all providers are
adequately informed about Lynch syndrome, obtain
comprehensive medical and family histories [39-41],
make referrals to genetics services [4] and recommend
appropriate screening and management [3,34,36]. How-
ever, significant gaps exist in providers knowledge
[12,42] and many fail to identify at-risk individuals and/
or advise them appropriately [39,42].
The evidence suggests that the health care system can
pose barriers to screening. Ineffectual coordination and
continuity of care [43], inadequate access to and avail-
ability of screening/specialty services [44], and variation
in provider recommendations [39,43] can impede effec-
tive clinical management. Currently, there is a paucity of
research on how individuals interact with the health
care system as they adjust to living with a confirmed
hereditary cancer risk.
This article reports on findings derived from a
grounded theory study on the psychosocial and beha-
vioral impact of genetic testing on individuals at high
risk for Lynch syndrome. In this paper we focus on how
confirmed carriers experience disease management and
view the quality of interactions with health care provi-
ders and the overall health care system. We include
recommendations on how to improve disease manage-
ment and facilitate quality outcomes.
Methods
Study design
A grounded theory study was part of a multiphase pro-
ject examining the psychosocial and behavioral impact
of DNA testing for Lynch syndrome. The Human Inves-
tigation Committee, Memorial University, approved the
study protocol.
Grounded theory was used during data collection and
analysis [45]. This approach is considered appropriate as
the focus is not solely on how health threats, diagnostic
procedures or treatment protocols are experienced, but
also on how this information is received and assimilated
into belief structures, and how this integration becomes
a stimulant for actions needed to achieve optimal health
functioning. The strength of this inductive approach is
the emphasis placed on identifying and describing the
social-psychological processes grounded in the data
emerging from participant interviews [46].
Population and predictive genetic testing
The target population was individuals from high and
intermediate risk families registered in the Provincial
Medical Genetics Program of Newfoundland and Labra-
dor (NL) and participating in the larger case control
study. Eligible participants for the grounded theory
study were those living in families with a confirmed
MSH2 mutation-the intron 5 splice site mutation (942
+3A > T) (12 families) or exon 8 deletion (5 families).
Details on this population have been reported elsewhere
[6].
A purposive sample of 39 individuals from 10 families
who had completed genetic testing and knew their sta-
tus was selected from the accessible population (N =
276). Predictive DNA testing is offered to individuals in
high and intermediate risk families. Follow-up counsel-
ing sessions are held with those interested in testing for
known mutations. Testing results are normally reported
in face-to-face sessions. Follow-up letters summarizing
the results are forwarded to participants and their physi-
cians. Clinical screening programs are adjusted accord-
ing to test results.
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female, 9 male) from three families with the intron 5
splice site mutation and three families with the exon 8
deletion (Table 1). The mean time from genetic testing
to the initial interview was 6.0 (± 2.8) years (range .1 to
9.6) and age at the first interview was 48.9 (± 13.6)
years (range 26 to 78). Thirteen participants developed
cancer at a mean age of 43 (± 5.8) years (range 33 to
54). Significantly, those who had reached the affected
stage experienced a total of 27 primary cancers with
CRC occurring at least once in 61.5% of the cases. Of
the 14 female carriers, five developed endometrial can-
cer (35.7%) and four (28.6%) had prophylactic hysterec-
tomies and/or oophorectomies.
Procedure
After initial contact, interested individuals were for-
warded a cover letter, brief study summary and consent
form, and re-contacted to schedule interviews. Following
informed, written consent, two interviewers (principal
investigator and research assistant) conducted 60 to 90
minute interviews with participants. Individual or small
group interviews (immediate family only) took place in
participants’ homes or conference rooms. Open-ended
questions elicited commentary on experiences with can-
cer in the family (first awareness of hereditary link, per-
ceived personal risk, screening motivation) and genetic
testing (decision-making, counseling experiences, reac-
tion to status, understanding implications, impact on
family). Additional questions evolved from the thematic
content analysis (adjusting to carrier status, screening
experiences, health care service needs). A second inter-
view provided participants with an opportunity to com-
ment upon and confirm their interpretive summaries.
Information from the second interview also helped the
research team augment gaps in the data, and the con-
ceptual categories and properties of the emerging sub-
stantive theory.
Data analysis
Data analysis proceeded in several phases. First, inter-
views were transcribed verbatim and perused indepen-
dently by a three-member team. The focus was on
interpreting the meaning of words and sentences
through reading and re-reading the text, and assigning
substantive codes to recurrent themes. Team discussions
focused on achieving consensus on emerging themes.
Second, mid-way through data collection, interviewing
was temporarily stopped and the constant-comparative
method of analysis applied to the data sets by two mem-
bers working independently. The objective was to iden-
tify relationships between and among substantive codes.
As potential category relationships were tested within
the data, a substantive theory began to emerge.
Third, in-depth analysis of the first 18 transcripts
revealed a family context (i.e., experiential base and
degree of burden and sense of resilience), differences
between carriers and non-carriers of Lynch syndrome
(views of screening protocols and timelines to diagnosis,
coping approaches to short/long term prognosis, impli-
cations for children) and differences between affected
and unaffected carriers (intensity of reactions to cancer
onset/recurrences). The focus shifted to purposive selec-
tion of an additional 14 carriers from family groupings
with many (n = 9) having reached the affected stage.
This approach to subject selection facilitated confirma-
tion of the substantive codes and refinement of their
properties.
In the later stages of analysis, length of time since dis-
covery of the family-based gene mutation and the avail-
ability of and actual involvement in genetic testing
surfaced as potential influencing factors on individual
and family perceptions. The decision was made to
Table 1 Participant characteristics (N = 23)
ID Family Gender Post-
GT
a
Age
b Affected Onset
Age
Cancer
Types
c
23 1B Female 6.42 57 No ——
24 1B Female 6.42 78 Yes 46 CRC/EC
25 1B Male 8.50 52 Yes 42 CRC/GA
26 1B Female 2.42 32 No ——
31 1B Male 7.50 47 Yes 45 CRCx2
8 1C Male 3.67 28 No ——
22 1C Male 6.50 26 No ——
30 1C Male 7.42 57 No ——
9 2A Female 8.08 41 Yes 39 CRCx2
32 2A Female 9.58 69 Yes 35 CRCx2/EC/
GA/SK
20 2B Female 9.08 50 Yes 33 EC/BR/VA
21 2C Male 9.08 50 No ——
10 3A Female 7.00 42 No ——
27 3A Female 8.17 51 Yes 43 Ovarian
28 3A Male 8.17 43 Yes 45 CRC/DUO
29 3A Female 7.50 33 No ——
11 3B Male 8.42 76 Yes 39 CRCx2/SK/KD
4 6 Female 0.75 48 Yes 49 CRC
19 6 Female 0.08 63 Yes 54 SK
37 7 Female 3.17 50 Yes 46 KD/EC
38 7 Male 3.08 46 No ——
34 8 Female 2.83 43 Yes 40 EC
36 8 Female 3.75 42 No ——
Note. Families 1B to 3B have the intron 5 mutation and families 6 to 8 have
the exon 8 deletion. The use of A, B or C after the family number denotes
separate nuclear families within a particular extended family.
a Years since genetic testing.
b Age at first interview.
c CRC = colorectal; EC = endometrial; GA = gastric; SK = skin; BR = breast; VA
= vaginal;
KD = kidney; DUO = duodenal.
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tance of time. Data collection continued (n = 7) until
the research team was confident that the experiences of
this group would not alter existing properties or cate-
gories. At the final step, the data and resulting theory
were examined by an independent consultant to
enhance credibility and accuracy. This resulted in a
more parsimonious and refined set of themes and codes.
Results
Data analysis revealed several personal, provider and
health system barriers to and/or facilitators of effective
disease management. Risk perceptions and acceptance
of the genetic link to cancer influenced individuals’ abil-
ity to adjust to their carrier status and accept recom-
mended regimes. Despite the importance of risk
perceptions and acceptance, interactions with the health
care system and providers clearly affected overall
adjustment.
Person-Centered Barriers/Facilitators
The most important personal factors were emotional
and psychosocial states, physical health status, prior
experiences with cancer screening and/or treatment, and
accepting the need for prophylactic interventions. These
factors are categorized as risk perceptions and decision-
making, and enduring screening/disease management.
Risk perceptions and decision-making
Risk perceptions play a crucial role in motivating indivi-
duals to become involved in disease management. A
m e a n i n g f u lb a l a n c em u s tb ef o r g e db e t w e e nt h ec o g n i -
tive and emotional spheres for decision-making. Full
engagement seems to be highly contingent upon emo-
tionally accepting potential threats to the self and
understanding the benefits of ongoing monitoring and
timely interventions.
Participants spoke about the emotional and physical
challenges of living with Lynch syndrome. Despite
understanding the importance of following recom-
mended protocols, the burden of dealing with this dis-
ease can be overwhelming.
L i k eIc a ns i th e r ea n ds a yt oy o u ,‘Oh yeah, all the
knowledge in the world, it’s great to know. But look
at it from the human part of it, your own self going
through this every single day’. Every time someone
goes to a doctor, my crowd is like, ‘Who is next,
right?’ It gets to you after a while. [I10, Fam3A]
All participants echoed the importance of screening
while being ever mindful of the challenge of living
with high cancer risk. Only one participant had not
engaged in cancer screening following a positive
genetic test result. However, not all of the participants
were participating in the full scope of cancer screen-
ing and/or adhering to recommended intervals. Oscil-
lating cognitive and emotional forces impinge on
individuals’ willingness to become fully involved in the
process.
Although some participants had misgivings about
knowing their status, these doubts soon subsided when
screening detected cancer. Several individuals alluded to
the potential benefits of regular screening.
I started seeing [gynecologist] on a regular basis. I
was constantly being screened; it [uterine cancer]
was picked up. I had the Pap smear and then the
endometrial biopsy and both of that came back
abnormal. It [cancer] was just in the early stages.
[I37, Fam7]
Participants also recognized the need to accept and
assume responsibility for healthy living and self moni-
toring for signs and symptoms of an impending illness.
Some perceived this as critical for disease management.
Since I found out that I have the gene, I try to eat a
little better and ... exercise a little better. You watch
for things and you’r eal i t t l em o r ec o n s c i o u so ft h e
things you’re putting in your body. [I26, Fam1B]
How well individuals adjusted to the burden of the
disease had important implications for their willingness
to follow recommended guidelines. Everyone who
accepted having Lynch syndrome recognized the bene-
fits of disease management. For some, the motivation to
do so was enhanced following early cancer detection.
Enduring screening and disease management
Participants often experienced conflicting emotions
about knowing what had to be done, wanting to do it
and actually doing it. For many, scheduling appoint-
ments and waiting for diagnostic test results became
physically draining, time consuming, and burdensome.
Successful adjustment seemed highly contingent upon
living as normal a life as possible without being con-
stantly reminded of cancer risk. The anxiety and worry
associated with the probability of cancer detection cre-
ated emotional barriers that impeded actions, forcing
some to use “time out” periods.
I’m after falling off the wagon a bit, where I’ve had a
couple of surgeries. ... I couldn’t do one test because
I was doing something else. ...Then after one of the
surgeries, I guess you kind of reach your tolerance
level. It was a conscious decision. ...I just had to give
it up for a while. [I9, Fam2A]
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ance. Although the full scope of physical and emotional
difficulties was individual specific and time dependent,
many commented on the challenges of regular screen-
ing. Even when highly motivated, the emotional strain
of upcoming procedures can be quite burdensome espe-
cially when prior experiences evoke unpleasant mem-
ories: “It’s just as well to tell the truth, I cry. I’m weeks
before thinking about it and I’m dreading it. I’m dread-
ing the day that the test will come.” [I37, Fam7]
For many participants, the type and frequency of
screening protocols and recommended prophylactic
interventions increased with evolving knowledge and/or
emerging cancer patterns within the family. The increas-
ing demands often became a struggle:
“It [screening] is cumulative and I find more and
more. I don’t dwell on it, but it’s changing and I find
I’m really, really sick of having to have this...” [I34,
Fam8]
Ongoing disease management requires adequate
resources to support everyday living. The significance of
this for any one person can be influenced by their finan-
cial status, family responsibilities and employment his-
tory, among others. For many, accessing appropriate
cancer care involves having the means and willingness
to travel outside of their communities, taking time off
work and/or having adequate support to deal with
family responsibilities. Practical issues are important
b e c a u s et h e ym a yi n t e r f e r ew i t ho n e ’s willingness and
ability to access recommended screening/treatment.
I’m a year in the hole on my sick leave here now. So
if I got a flu or anything like that, I can’tj u s ts t a y
home. Every appointment [for diagnostic tests],
where I’m running to town is over so many hours ...
it is sick leave. Then I had surgeries where you take
off six weeks. [I9, Fam2A]
When early stage cancer is identified, physical and
psychological benefits occur immediately following treat-
ment. These benefits may not be so obvious for indivi-
duals asked to consider prophylactic surgery in the
absence of signs and symptoms of disease. Female family
members are encouraged to have prophylactic hysterect-
omy and bilateral salpingo-oophorectomy because of
their high risk for endometrial and ovarian cancer, espe-
cially when parents or sisters have had these cancers. In
the current study, four women had prophylactic surgery
without having symptoms of disease whereas another
two had hysterectomies for benign gynecological disease.
The “present” for many participants reflects a story of
survivorship and endurance. It was apparent from listen-
ing to their stories that the burden of screening/treat-
ment sometimes became a deterrent to continuance.
This burden was augmented or lessened by the scope of
family and work responsibilities.
Provider-Centered Barriers/Facilitators
The perceived knowledge and skills of health care provi-
ders surfaced as key factors facilitating or impeding par-
ticipation in regular screening and disease management.
Participants wanted to receive care from physicians/spe-
cialists familiar with their family cancer history. Trust
seemed to increase when physicians were intimately
aware of the family history and acknowledged the
importance of monitoring high risk cancer sites.
When you get a doctor like that [open and engaging]
it means something because you don’tf e e ll i k e
you’re just a number, like they know you personally.
They seem like they care and you don’t come across
t o om a n yl i k et h a t .If e l tl i k ean u m b e rf o rs ol o n g .
[I27, Fam3A]
Most disconcerting for participants was the perceived
tendency for some physicians to discount age of onset
of first cancers in families as a benchmark for screening
initiation and follow-up. When physicians failed to do
this, participants distrusted their knowledge: “The pro-
blem is they are young and because they are young the
doctors aren’t testing [screening] them properly for
bowel cancer. Not testing them early enough. They’re
not realizing that even now after all this.” [I23, Fam1B]
Integral to effective monitoring is having knowledge of
the natural history of the disease. Following encounters
with physicians who seemed to have limited understand-
ing of Lynch syndrome, some participants felt the need
to become better informed and share this knowledge
with them.
Every time I go to him [physician] I say, ‘Now do
you know that these lesions are sometimes flat? ...
Don’t look for bumps. Look for these flat lesions
which are the Lynch II’. Even now I don’tk n o wi f
he hears me. Because they’ll always talk about
removing polyps and I don’tk n o wi ft h a t ’ss e to u t
enough in the literature. [I20, Fam2B]
Similar concerns were expressed about physicians not
perceived to be attentive enough to the extracolonic
cancers.
It would be nice if we knew it was being monitored
and we were all getting the proper checks. But not
only just for bowel. I mean they do a colonoscopy,
that’s not going to show if you have anything in
your ovaries or kidneys or anywhere else. [I23,
Fam1B]
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assessed physicians in terms of the completeness of
medical care and quality of communications. Medical
care was evaluated by the thoroughness of history taking
and physical examinations. If unsure about a physician’s
approach, participants felt the need to enlighten them.
Unless you can tell a doctor what is wrong with you
he can’t see through you and know, unless you
recognize symptoms yourself. Gone are the days
when ... they [physicians] do a complete physical and
chest x-ray. ...They don’tl o o ka ti t[ c a n c e r ]a sc o m -
ing from a history. [I32, Fam2A]
Quality of communications was defined in terms of
effective interpersonal skills. Participants wanted provi-
ders who were sincere and took the time to facilitate
understanding. Some commented on the limited com-
munication of an informative nature and the lack of per-
ceived support: “When I go for a colonoscopy, it’st h e
quicker you’re in and out the better. It’s no such thing
as sit down for any discussion. We got no support sys-
tem.” [I25, Fam1B]. Other participants presented a con-
trasting perspective.
When they found things that he [specialist] has been
suspicious about, he showed me the pictures and he
sits down. ‘This is what we are going to do’.. . . S o
he’s always been very informative. ...I appreciate that,
I want that honesty. ...So I can be actively involved
with what happens to me. [I21, Fam2C]
In essence, living with Lynch syndrome is an indepen-
dent journey that requires being attentive to physical
changes, appreciative of their implications for future
health, and assertive about receiving care from knowl-
edgeable, caring providers.
Health Care System Barriers/Facilitators
Continuity of care at the provider and system levels
seemed to pose great difficulty for participants. Continu-
ity of care is dependent upon continuous information
flow (disease and person-focused), strategic coordination
of services (complementary and timely), and accessing a
consistent provider mix over time. Restricted continuity
of care can play havoc with successful disease
management.
Especially vital is ongoing collaboration among pri-
mary and specialty care sectors during the planning and
delivery of services. As the number of diagnostic proce-
dures and potential cancer sites increase, there is a con-
comitant increase in the number of specialists involved
in providing care and, thus, the greater potential for
inconsistencies in recommended screening intervals. A
couple of participants voiced their frustrations following
interactions with different aspects of the health care sys-
tem: “But my family doctor argued that it [colonoscopy]
should be every year. I feel it should be done every year.
Every three years the [specialist] wants it done.” [I38,
Fam7]; “I haven’t been done since two years ago. That
extra six months could mean a lot to me. So what am I
supposed to do?” [I27, Fam3A]
Study participants were of the opinion that poor com-
munication among providers could be detrimental to a
person’s well-being, quality of life and, ultimately, long-
term survival. An important message conveyed is that
greater consensus is needed on acceptable screening
intervals and targets, especially in families with a higher
than usual penetrance rate for CRC and associated
cancers.
Participant comments also conveyed a vivid picture of
limited organization and coordination of health care.
Individuals confront challenges navigating the health
care system particularly when having to deal with differ-
ent institutions and physicians/specialists. At times, this
requires a tenacious, persistent approach and a working
knowledge of the system.
Every six months I ... have the ultrasound done. ...
Then I have to make an appointment to see the spe-
cialist ... for what? It is a negative ultrasound. Then
you’re supposed to ... get another ultrasound but
they can’tg e ta na p p o i n t m e n ts e tu pt h a tf a ri n
advance. ...then you need a requisition. [I9, Fam2A]
Everyone echoed the need for a more coordinated
approach that lessens the demands on personal time
and coping resources. One participant commented thus,
“I would like to have one stop shopping. It seems like I
am running around doing all this and I don’tw a n tt h i s .
I don’t need this.” [I4, Fam6]
Timely access to services can become a major liability,
with delays especially upsetting for individuals subject to
heightened uncertainty and worry. Participants sug-
gested that carriers should be given priority access to
screening and specialty services.
After I had my operation [for colon cancer] I
phoned up for another appointment [with specialist]
and they told me that it could be another six
months before I get in and my year was up then
right. ...So I phoned the doctor that operated on me
and I got in within two weeks. ...I was frightened
right. [I31, Fam1B]
Despite being aware of requisite health care services,
system challenges often prevented participants from
‘being ahead of the game’. Especially critical is a
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and follow-up. Without adequate resources, individuals
are at greater risk to be burdened by the disease.
Discussion
The current study highlights the many personal, provi-
der and system level barriers to and facilitators of enga-
ging in effective disease management. Study findings
suggest that participants seem to be well-informed
about Lynch syndrome, have accurate risk perceptions
and acknowledge the benefits of regular screening.
Nevertheless, the interaction of the emotional and physi-
cal burden of disease management with the practical
demands of everyday living (family and work) and provi-
der and health care system challenges may also signifi-
cantly influence behavior.
O n l yaf e ws t u d i e sh a v es t r e s s e dt h a tt h eb e h a v i o r a l
impact of genetic testing is an important area for
research [2,22,23,28]. Most studies have focused on psy-
chological outcomes as opposed to potential barriers to
and facilitators of informed decision-making concerning
screening/treatment regimes. The current study provides
informative insight into some of these factors. The find-
ings highlight the physical and psycho-emotional obsta-
cles (worries/concerns about potential test results/
prophylactic interventions, intensity and scope of
screening, preparation for and experiences with diagnos-
tic procedures, scheduling issues) that can increase the
burden of disease management. Other researchers have
noted that physical and psychological barriers can add
to the burden of screening, and pose deterrents to regu-
lar participation [11,14,20,32,47].
The importance of disease-related experiences for
facilitating adjustment and determining the appropriate-
ness and relevancy of healthy behaviors is not new. This
finding supports, in part, the argument put forth by
others that behavioral responses are a function of per-
ceived risk which is influenced by health threat repre-
sentations that continuously evolve in response to
experiences with the disease in the self and/or others
[25,30,31].
The current study also supports how interactions with
health care providers can impact the overall burden of
Lynch syndrome. Ratings of the quality of provider care
are a function of perceived knowledge levels and clinical
management approaches. A growing body of evidence
supports the significant role played by physicians and
other providers in improving adherence in this popula-
tion [13,16,33,34,43]. It is therefore important that all
providers become informed about current screening and
treatment protocols [16,35,48].
Several authors confirm the controversy over suitable
time intervals for colonoscopy [34,35,40,41] and the
variable attention given to extracolonic cancers [17,38].
These inconsistencies are worrisome. Previous research
has found that those at increased risk for CRC receive
insufficient information on screening intervals, risk
assessment and procedures, and inadequate emotional
support between diagnostic tests [20,43]. This situation
not only impedes development of best practice guide-
lines but also creates problems for physicians involved
in disease management [49,50].
Experiences with and reactions to encounters with the
health care system can impede effective disease manage-
ment. Our findings suggest that existing counseling and
disease management resources are inadequate to meet
the demands that follow predictive DNA testing. An
important source of dissatisfaction is gaining timely
access to needed services. Ineffective coordination of
diagnostic, treatment and specialists’ appointments cre-
ates unnecessary delays, enhances worry, and propels
some to distance themselves from the whole process. It
is apparent that referral protocols need to be simplified
and more coordinated. Some authors have highlighted
the need for a single service [12] or a multidisciplinary
team comprised of providers committed to following
evidence-informed clinical guidelines [12,20,38,39,50].
Our research illuminates the possibility of new roles
for health care providers in cancer genetics. In Canada
there is no national registry, as provided in some smaller
countries. In the province of NL four regional health
authorities (RHAs) are responsible for delivering a range
of health care services in hospitals, clinics and commu-
nity health programs within their respective geographic
areas. Recently, genetics clinics have been established in
three of these RHAs. These clinics will be linked to the
Provincial Medical Genetics Program which will inte-
grate clinical care with the evaluation of interventions
directed toward improving clinical outcomes. Other
researchers concur that familial cancer registries and
genetics service centers are perceived to be effective
mechanisms for facilitating quality outcomes [12,34,35].
Despite the limitations of a small sample size and
inherent biases in having participants recall how they
experienced and reacted to specific events and situa-
tions, the findings do provide practical insight into bar-
riers and facilitators that may be individual, provider
and/or system based.
Conclusions and Policy Implications
This study has further illuminated the psychosocial and
behavioral impact of predictive DNA testing for Lynch
syndrome. Many participants were confronted with ser-
ious issues in managing their disease. These issues
require preventive strategies to help maintain optimal
health and a reasonable quality of life. What is impor-
tant for families is the presence of providers with the
necessary knowledge and skill base and a coordinated
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health care and timely follow-up.
Ideally, genetic counseling should facilitate the adop-
tion of appropriate, lifelong disease management strate-
gies. In light of the current findings, genetic counselors
may need to assess the family and socio-cultural context
of hereditary cancer [24] and its potential influence on
decision-making. It is also necessary to explore the emo-
tional aspects of living with cancer risk so that the bur-
den of the disease can be lessened.
Importantly, Lynch syndrome has significant implica-
tions for public health policy [4]. The ultimate plan
should be to provide resources that enable individuals in
high risk families to develop a strong sense of resilience
and maintain a balanced screening schedule. In particu-
lar, this cohort requires timely and appropriate health
care services, including:
○ A critical mass of genetic counselors to provide
timely services to high risk families before, during
and following genetic testing.
○ Service providers to coordinate and streamline
diverse screening and treatment resources.
○ Health care providers, especially primary care phy-
sicians, informed about the risk of cancer within
families and reinforcing the importance of maintain-
ing recommended screening and initiating referrals
to appropriate specialists.
○ Clinical monitoring tools designed to evaluate the
impact of predictive testing and the ongoing psycho-
social and behavioral adjustment to living in families
with hereditary cancer.
The current uncoordinated, physician dependent orga-
nization of screening for individuals with Lynch syn-
drome in Canada is inadequate. Given the incidence and
prevalence of these hereditary cancers and the clinical
benefits of screening, there is a critical need to provide
integrated health care and timely follow-up in a manner
that facilitates navigation of and access to the health
system.
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